POMATI, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 507
EU - Europa 326
AS - Asia 52
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 888
Nazione #
US - Stati Uniti d'America 497
IT - Italia 183
SE - Svezia 78
IN - India 34
DE - Germania 20
RO - Romania 15
CA - Canada 10
CN - Cina 8
IR - Iran 6
NL - Olanda 5
FR - Francia 4
GB - Regno Unito 4
IE - Irlanda 4
UA - Ucraina 4
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
AT - Austria 1
EE - Estonia 1
ES - Italia 1
EU - Europa 1
IL - Israele 1
JP - Giappone 1
SC - Seychelles 1
TG - Togo 1
Totale 888
Città #
Fairfield 90
Chandler 59
Rome 53
Houston 39
Ashburn 30
Woodbridge 30
Seattle 29
Cambridge 23
San Paolo di Civitate 23
Wilmington 22
Dearborn 20
Princeton 17
Bremen 15
Lawrence 13
Ann Arbor 10
Horia 9
Millbury 8
Portici 8
Boston 7
San Diego 7
Fremont 6
Redwood City 5
Toronto 5
Dublin 4
Milan 4
Plano 4
Amsterdam 3
Beijing 3
Boardman 3
Norwalk 3
Ottawa 3
Andover 2
Dubai 2
Galdo 2
Guardiagrele 2
Kunming 2
London 2
Mumbai 2
Padova 2
Phoenix 2
Sofia 2
Zanjan 2
Anagni 1
Antrodoco 1
Anzio 1
Azor 1
Barletta 1
Carlentini 1
Caserta 1
Chengdu 1
Chennai 1
Chieti 1
Dallas 1
Des Moines 1
Frosinone 1
Groningen 1
Hyderabad 1
Imola 1
Jinan 1
Kish 1
Livorno 1
Lomé 1
Madrid 1
Massa 1
Montichiari 1
Montréal 1
Prato 1
Quinto Vicentino 1
Reggio Calabria 1
Rignano Flaminio 1
Sacramento 1
San Mateo 1
Shenyang 1
Tallinn 1
Toulouse 1
Turin 1
Venezia 1
Vienna 1
Vigevano 1
Winnipeg 1
Totale 615
Nome #
Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza" University of Rome Head and Neck Unit clinical recommendations 118
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience 110
Burned-out testicular cancer: really a different history? 94
Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO) 73
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience 68
The 5-Ws of immunotherapy in head and neck cancer 59
The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study 59
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era 58
The impact of locoregional treatment on response to Nivolumab in advanced platinum refractory head and neck cancer: the NEED TRIAL 54
The role of opioids in cancer response to immunotherapy 52
Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma 48
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1 46
Standard of care and promising new agents for the treatment of mesenchymal triple-negative breast cancer 42
Primary squamous cell carcinoma of major salivary gland: “Sapienza Head and Neck Unit” clinical recommendations 29
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence 25
Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology 16
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy 11
Genomic and immune approach in platinum refractory HPV-negative head and neck squamous cell carcinoma patients treated with Immunotherapy: a novel combined profile 10
Network analysis to determine association between immuno-related toxicities and immune soluble profile in patients treated with anti-PD-1 10
Antibiotics, the microbiome and gastrointestinal cancers: a causal interference? 5
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach 4
Totale 991
Categoria #
all - tutte 1852
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1852


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20183 0000 00 00 0003
2018/201954 0043 00 00 051329
2019/2020158 13637 1034 1517 1519109
2020/2021188 1391245 815 124 1823821
2021/2022254 41151212 2814 617 1476325
2022/2023328 51633336 4332 1933 18000
Totale 991